Skip to main content
Journal cover image

Morbilliform Eruptions: Differentiating Low-Risk Drug Eruptions, Severe Cutaneous Adverse Reactions, Viral Eruptions, and Acute Graft-Versus-Host Disease.

Publication ,  Journal Article
Yan, A; Madigan, L; Korman, A; Shearer, S; Dulmage, B; Patel, T; Milani-Nejad, N; Chung, C; Fisher, K; Kaffenberger, B
Published in: Am J Clin Dermatol
May 2025

Morbilliform eruptions, which are a clinical reaction pattern characterized by erythematous macules and papules coalescing into patches that cover most of the skin surface, are one of the most common cutaneous findings in the inpatient setting. In the hospital setting, most causes are benign and due to low-risk drug exanthems; however, morbilliform eruptions may also be a sign of high-risk diseases, including Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome, acute generalized exanthematous pustulosis, and graft-versus-host disease. Proper identification of the etiology and risk stratification of a morbilliform eruption is critical to ensure proper management and optimize patient outcomes. In this review, we discuss the key features that differentiate high-risk from low-risk morbilliform eruptions, as well as specific characteristics that differentiate the different high-risk eruptions. Additionally, we offer a clinical algorithm that may be applied in the management of a patient who presents with a morbilliform rash.

Duke Scholars

Published In

Am J Clin Dermatol

DOI

EISSN

1179-1888

Publication Date

May 2025

Volume

26

Issue

3

Start / End Page

379 / 393

Location

New Zealand

Related Subject Headings

  • Stevens-Johnson Syndrome
  • Skin
  • Risk Factors
  • Risk Assessment
  • Humans
  • Graft vs Host Disease
  • Drug Hypersensitivity Syndrome
  • Drug Eruptions
  • Diagnosis, Differential
  • Dermatology & Venereal Diseases
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Yan, A., Madigan, L., Korman, A., Shearer, S., Dulmage, B., Patel, T., … Kaffenberger, B. (2025). Morbilliform Eruptions: Differentiating Low-Risk Drug Eruptions, Severe Cutaneous Adverse Reactions, Viral Eruptions, and Acute Graft-Versus-Host Disease. Am J Clin Dermatol, 26(3), 379–393. https://doi.org/10.1007/s40257-025-00924-0
Yan, Allison, Lauren Madigan, Abraham Korman, Sabrina Shearer, Brittany Dulmage, Tejesh Patel, Nima Milani-Nejad, Catherine Chung, Kristopher Fisher, and Benjamin Kaffenberger. “Morbilliform Eruptions: Differentiating Low-Risk Drug Eruptions, Severe Cutaneous Adverse Reactions, Viral Eruptions, and Acute Graft-Versus-Host Disease.Am J Clin Dermatol 26, no. 3 (May 2025): 379–93. https://doi.org/10.1007/s40257-025-00924-0.
Yan A, Madigan L, Korman A, Shearer S, Dulmage B, Patel T, et al. Morbilliform Eruptions: Differentiating Low-Risk Drug Eruptions, Severe Cutaneous Adverse Reactions, Viral Eruptions, and Acute Graft-Versus-Host Disease. Am J Clin Dermatol. 2025 May;26(3):379–93.
Yan, Allison, et al. “Morbilliform Eruptions: Differentiating Low-Risk Drug Eruptions, Severe Cutaneous Adverse Reactions, Viral Eruptions, and Acute Graft-Versus-Host Disease.Am J Clin Dermatol, vol. 26, no. 3, May 2025, pp. 379–93. Pubmed, doi:10.1007/s40257-025-00924-0.
Yan A, Madigan L, Korman A, Shearer S, Dulmage B, Patel T, Milani-Nejad N, Chung C, Fisher K, Kaffenberger B. Morbilliform Eruptions: Differentiating Low-Risk Drug Eruptions, Severe Cutaneous Adverse Reactions, Viral Eruptions, and Acute Graft-Versus-Host Disease. Am J Clin Dermatol. 2025 May;26(3):379–393.
Journal cover image

Published In

Am J Clin Dermatol

DOI

EISSN

1179-1888

Publication Date

May 2025

Volume

26

Issue

3

Start / End Page

379 / 393

Location

New Zealand

Related Subject Headings

  • Stevens-Johnson Syndrome
  • Skin
  • Risk Factors
  • Risk Assessment
  • Humans
  • Graft vs Host Disease
  • Drug Hypersensitivity Syndrome
  • Drug Eruptions
  • Diagnosis, Differential
  • Dermatology & Venereal Diseases